Last $0.0090 USD
Change Today 0.00 / 0.00%
Volume 3.4M
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

bioheart inc (BHRT) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/14 - $0.08
52 Week Low
01/12/15 - $0.0070
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOHEART INC (BHRT)

Related News

No related news articles were found.

bioheart inc (BHRT) Related Businessweek News

No Related Businessweek News Found

bioheart inc (BHRT) Details

Bioheart, Inc., a development stage biotechnology company, focuses on the discovery, development, and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage, and degenerative diseases. Its lead product candidate is MyoCell, a clinical muscle-derived cell therapy that has completed Phase II-a study and populates regions of scar tissue within a patient’s heart with new living cells for improving cardiac function in chronic heart failure patients. The company also develops MyoCell SDF-1, an autologous cell therapy treatment for severe chronic damage to the heart and cells modified to express angiogenic factors; AdipoCell, an adipose cell therapy treatment for the management of progressive heart failure; and MyoCath, a disposable endoventricular catheter used for the delivery of biologic solutions to the myocardium. In addition, its preclinical stage product candidates include MyoCath II, which provides multidirectional cell injection, as well as is used for the delivery of biologic solutions to the myocardium. Bioheart, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

4 Employees
Last Reported Date: 12/23/14
Founded in 1999

bioheart inc (BHRT) Top Compensated Officers

Chief Executive Officer, President, Chief Fin...
Total Annual Compensation: $766.7K
Chief Scientific Officer, Director and Member...
Total Annual Compensation: $284.2K
Compensation as of Fiscal Year 2013.

bioheart inc (BHRT) Key Developments

Bioheart, Inc., Special/Extraordinary Shareholders Meeting, Feb 02, 2015

Bioheart, Inc., Special/Extraordinary Shareholders Meeting, Feb 02, 2015., at 09:00 US Eastern Standard Time. Location: 13794 NW 4 Street. Agenda: To elect seven directors of the company; to ratify the appointment of Fiondella, Milone, and LaSaracina LLP, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2015; to approve the 2013 Omnibus Equity Compensation Plan; to consider and, if deemed advisable, approve an advisory vote on executive compensation; to consider an advisory vote determining the frequency of future executive compensation advisory votes; and to transact such other business as may properly come before the Meeting.

Bioheart, Inc. Announces Positive 12 Month Preliminary Data From Phase I Angel Trial

Bioheart, Inc. released the preliminary 12 month data from its phase I ANGEL Trial. Fully funded by Bioheart, the trial is being conducted in Mexico at the Hospital Angeles in conjunction with the Regenerative Medicine Institute (RMI). At the 12 month time point, patients are demonstrating a statistically significant average improvement in ejection fraction (EF) by echocardiogram. At the 3 month time point, 100% of the patients demonstrated either improvement or stayed the same. After 3 months, patients showed an average absolute improvement of 3 percentage points in EF. The patients continued to improve from 3 months to 6 months with a statistically significant average absolute improvement of 10 percentage points (p=0.01) and at the 12 month follow up patients showed this same level of improvement (p=0.01). This phase I study will provide necessary safety and preliminary efficacy of adipose derived stem cells (AdipoCell(TM)) in patients with congestive heart failure. Endpoints include safety, exercise capacity, quality of life, and ejection fraction at 3 months, 6 months and 12 months.

Bioheart Announces Opening of Laboratory and Clinic in South Africa

Bioheart, Inc. announced the opening the laboratory and clinic in South Africa. The facilities in South Africa opening will be able to provide cell therapies in the clinic as well as cell culture expansion and cryopreservation to local patients. Bioheart can multiply and preserve an individual's cells in sub-zero temperatures for future treatments as required. Bioheart's partnership will establish a critical relationship with the South African government and the joint venture will work closely with the Ministry of Health to make Bioheart protocols part of the standard of care for patients in South Africa and neighboring countries. Bioheart has provided the necessary training and expertise to transfer Bioheart therapies to the new facility. Bioheart will assume 49% ownership of the new entity. Dr. Walter Bell and his team will offer these therapies to the more than 51 million people living in South Africa as well as being a premier site for medical tourism.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BHRT:US $0.01 USD 0.00

BHRT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cesca Therapeutics Inc $0.91 USD +0.0043
Cytori Therapeutics Inc $1.12 USD -0.01
International Stem Cell Corp $0.06 USD 0.00
Nuo Therapeutics Inc $0.26 USD -0.0175
StemCells Inc $1.12 USD +0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation BHRT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOHEART INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at